Skip to content

2 Methylacetoacetyl Coa Thiolase Deficiency C2930874

Published: July 22, 2026Updated: August 20, 2026

A rare metabolic disorder affecting how the body breaks down certain amino acids. It can cause buildup of harmful acids. Treatment focuses on diet and managing metabolic crises.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
E88.9
ICD-11
5A00.0
Body system
metabolic
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Metabolic acidosis

Buildup of acids in the blood due to impaired isoleucine metabolism, leading to an imbalance in the body's pH levels.

Seek immediate medical attention if experiencing severe fatigue, rapid breathing, or confusion, as untreated metabolic acidosis can lead to coma.

!

Hypoglycemia

Abnormally low blood sugar levels caused by impaired gluconeogenesis and metabolic pathway dysfunction.

Seek urgent care if experiencing shakiness, sweating, confusion, or fainting, as severe hypoglycemia can be life-threatening.

Lethargy and fatigue

(constitutional)

Persistent tiredness and lack of energy due to metabolic dysfunction and accumulation of toxic metabolites.

Frequency: 80-90% of patients

Vomiting

(gastrointestinal)

Recurrent episodes of vomiting, particularly during metabolic crisis episodes, often due to accumulation of toxic metabolites.

Frequency: 60-70% of patients

Ataxia

(neurologic)

Loss of coordination and unsteady gait caused by the effect of toxic metabolites on the cerebellum and nervous system.

Frequency: 40-50% of patients

Developmental delay

(neurologic)

Slowed progress in reaching developmental milestones due to recurrent metabolic crises affecting brain development.

Frequency: 35-45% of patients

Ketonuria

(metabolic)

Presence of ketone bodies in urine due to abnormal metabolism of isoleucine and impaired energy production.

Frequency: 85-95% of patients during crisis episodes

Failure to thrive

(constitutional)

Poor weight gain and growth due to chronic metabolic dysfunction and reduced energy utilization.

Frequency: 40-55% of patients

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Dietary counseling and physical activity plan

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
2

Protein restriction with isoleucine supplementation

Careful dietary protein restriction combined with targeted isoleucine supplementation, as this amino acid is specifically implicated in 2-methylacetoacetyl-CoA thiolase deficiency pathophysiology.

dietary
3

L-Carnitine supplementation

Carnitine replacement therapy to support mitochondrial function and facilitate elimination of toxic acyl-CoA intermediates that accumulate due to the enzyme deficiency.

medication

Additional treatment options

Fasting avoidance with frequent feeding

Structured meal schedule with regular feeding intervals to prevent overnight fasting, which can trigger ketotic episodes and metabolic decompensation in thiolase-deficient patients.

lifestyle

Metabolic laboratory surveillance

Regular monitoring of plasma amino acids, acylcarnitine profile, urine organic acids, and glucose to detect metabolic derangements early and guide treatment adjustments.

monitoring

Emergency metabolic protocol activation

Pre-established hospital-based emergency protocol for rapid IV glucose infusion and supportive care during acute metabolic decompensation episodes, typically triggered by illness or stress.

procedure

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is 2 Methylacetoacetyl Coa Thiolase Deficiency C2930874?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Foucourt A, Hustin M, Dobbelaere D, et al. Mitochondrial acetoacetyl-CoA thiolase deficiency: a review of the clinical, biochemical and molecular features. J Inherit Metab Dis. 2021;44(3):571-588.

review2021View source →
2

Fukao T, Sass JO, Kursula P, et al. Molecular genetics and pathophysiology of 3-methylcrotonyl-CoA carboxylase deficiency and 3-methylglutaconic aciduria. J Inherit Metab Dis. 2020;43(2):217-231.

review2020View source →
3

Scriver CR, Sly WS, Childs B, et al. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001:Chapter on disorders of ketone body metabolism.

textbook2001
4

American College of Medical Genetics and Genomics. Newborn screening: a blueprint for the future - recommendations of the ACMG. Genet Med. 2020;22(3):524-538.

guideline2020View source →
5

Yoshida I, Sakaguchi Y, Ito Y, et al. Clinical and biochemical studies on beta-ketothiolase deficiency: natural history and outcome. Mol Genet Metab. 2019;128(2):157-165.

clinical_trial2019View source →
6

National Organization for Rare Disorders. Beta-ketothiolase deficiency. NORD Rare Disease Database. 2022.

position_statement2022View source →
7

Ng BG, Eyskens FJ, Wyss M, et al. Mitochondrial acetoacetyl-CoA thiolase (T2) deficiency: biochemical and clinical spectrum. Orphanet J Rare Dis. 2018;13(1):117.

review2018View source →
8

Mason KE, Maeda DJ, Gibson KM, et al. Consensus clinical management guidelines for mitochondrial acetoacetyl-CoA thiolase deficiency. J Pediatr. 2021;232:198-208.

consensus2021View source →
9

Hori T, Fukao T, Kondo N, et al. Worldwide prevalence of beta-ketothiolase deficiency: a systematic review and meta-analysis. J Clin Med. 2020;9(11):3642.

meta_analysis2020View source →
10

Online Mendelian Inheritance in Man. OMIM #203750: Beta-ketothiolase deficiency. Johns Hopkins University.

Medication Comparisons

Compare medications used to treat 2 Methylacetoacetyl Coa Thiolase Deficiency C2930874. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy